Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

10.16 -1.00 (-8.96%)
Official Closing Price Updated: 8:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cybin Inc

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression
Cybin starts Phase 3 trials for its depression treatment, CYB003, backed by strong Phase 2 data and a solid cash position. 
Via Benzinga
EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program
Cybin secures a U.S. patent for its CYB005 program targeting CNS disorders and prepares to launch a Phase 3 trial for CYB003 in major depressive disorder. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Leadership Shake-Ups In Cannabis And Psychedelics: Maryland's Cannabis Chief Resigns, Costly Legal Battle In MA Drags On & More
Maryland transitioned to an adult-use cannabis market a little over a year ago. Led by the state's Cannabis Administration Director, Will Tilburg, the transition resulted in the state's legal cannabis... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
CYBN Stock Earnings: Cybin Beats EPS for Q1 2024
CYBN stock results show that Cybin beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy. 
Via Benzinga
CYBN Stock Earnings: Cybin Beats EPS for Q4 2023
CYBN stock results show that Cybin beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Cybin Inc. Q3 Earnings: Clinical Advances Amid Financial Loss
The TDR Three Key Takeaways: 
Via Benzinga
3 Biotech Stocks That Could Make Your Summer Unforgettable
If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider. 
Via InvestorPlace
Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns
Psychedelics could be a game-changer in treating mental health issues, creating substantial opportunities for top psychedelic stocks. 
Via InvestorPlace
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
These are three of the best psychedelic stocks to buy on the dip for potentially lucrative future growth and returns. 
Via InvestorPlace
Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development
Explore Cybin Inc.'s FY 2024 results: $78M loss and strides in psychedelic therapy for mental health. Read now! 
Via Benzinga
Latest Executive Cannabis Changes You Should Know About: Curaleaf, Planet 13 Elect Directors And More
As the premier gathering of top entrepreneurs and investors is taking place this Monday in New Jersey, let's scroll through the latest leadership changes in the cannabis and psychedelics... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision. 
Via Benzinga
Exposures Product Safety
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
Via Benzinga
Topics Cannabis
Exposures Cannabis
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Via Benzinga
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
Penny stocks are incredibly risky. However, if you can handle the heat, these ideas might be worth your while. 
Via InvestorPlace
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Via Benzinga
Topics Economy
Exposures Interest Rates
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement
Via Benzinga
Exposures Product Safety
3 High-Potential Penny Stocks to Turn $1000 into $1 million
U.S. equities are in the midst of a steady rally, but these high-potential penny stocks are likely to trounce the major indices. 
Via InvestorPlace
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Via Benzinga
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Via Benzinga
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian... 
Via Benzinga
FDA Green Lights Cybin's Psychedelic Clinical Study Assessing Generalized Anxiety
Cybin will advance the clinical development of the novel psychedelic molecule CYB004 for generalized anxiety treatment. 
Via Benzinga
Exposures Product Safety
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.  
Via Benzinga
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD 
Via Benzinga
30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond
The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substances like psilocybin and MDMA to treat mental health... 
Via Benzinga
Cybin Inc's Two Deuterated Psychedelic Molecules Achieve Positive Topline Clinical Results
Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) announced positive safety and efficacy data from its Phase 1 studies of CYB004 (intravenous administration) and SPL028 (intravenous and... 
Via Benzinga
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 1, 2024
Via Benzinga
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
The increased understanding and widespread acceptance of mental health concerns have put psychedelic stocks in the spotlight. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.